First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
Go back to First Patient Dosed in ProstACT Program for Prostate Cancer Therapy| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 10.06 -0.04 (0.4%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.10 | 52 Week High | $2.18 | |||
| Open | $10.04 | 52 Week Low | $0.30 | |||
| Day High | $10.06 | P/E | N/A | |||
| Day Low | $9.94 | EPS | $-3.32 | |||
| Volume | 68,379 | |||||
